Long-term efficacy and safety of eculizumab in Japanese patients with paroxysmal nocturnal haemoglobinuria.

Trial Profile

Long-term efficacy and safety of eculizumab in Japanese patients with paroxysmal nocturnal haemoglobinuria.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2014

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 08 Jul 2014 New trial record
    • 11 Aug 2013 Results published in the International Journal of Haematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top